Genetic imputation has become standard practice in modern genetic studies. However, several important issues have not been adequately addressed including the utility of study-specific reference, performance in admixed populations, and quality for less common (minor allele frequency [MAF] 0.005-0.05) and rare (MAF < 0.005) variants. These issues only recently became addressable with genome-wide association studies (GWAS) follow-up studies using dense genotyping or sequencing in large samples of non-European individuals. In this work, we constructed a study-specific reference panel of 3,924 haplotypes using African Americans in the Women's Health Initiative (WHI) genotyped on both the Metabochip and the Affymetrix 6.0 GWAS platform. We used this reference panel to impute into 6,459 WHI SNP Health Association Resource (SHARe) study subjects with only GWAS genotypes. Our analysis confirmed the imputation quality metric Rsq (estimated r 2 , specific to each SNP) as an effective post-imputation filter. We recommend different Rsq thresholds for different MAF categories such that the average (across SNPs) Rsq is above the desired dosage r 2 (squared Pearson correlation between imputed and experimental genotypes). With a desired dosage r 2 of 80%, 99.9% (97.5%, 83.6%, 52.0%, 20.5%) of SNPs with MAF > 0.05 (0.03-0.05, 0.01-0.03, 0.005-0.01, and 0.001-0.005) passed the post-imputation filter. The average dosage r 2 for these SNPs is 94.7%, 92.1%, 89.0%, 83.1%, and 79.7%, respectively. These results suggest that for African Americans imputation of Metabochip SNPs from GWAS data, including low frequency SNPs with MAF 0.005-0.05, is feasible and worthwhile for power increase in downstream association analysis provided a sizable reference panel is available. Genet. Epidemiol. 36:107-117, 2012. C 2012 
INTRODUCTION
Genotype imputation has become standard practice to increase genome coverage and improve power in genomewide association studies (GWAS) and meta-analysis [de Bakker et al., 2008; Li et al., 2009; Marchini and Howie, 2010] . The wealth of literature using genotype imputation has focused on using external reference panels (for example, phased haplotypes from the International HapMap Project [The International HapMap Consortium, 2007] or the 1000 Genomes Project [The 2010]), largely in individuals of European ancestry, for inference of genotypes at common (minor allele frequency [MAF] > 0.05) genetic markers.
GWAS have identified more than 4,300 genetic variants associated with human diseases and traits (http:// www.genome.gov/gwastudies/) . Investigators across the world have begun efforts to fine map within regions where GWAS-identified SNPs reside, through dense genotyping (e.g., using regioncentric or gene-centric chips such as the Metabochip for metabolic-related traits [http://www.sph.umich.edu/ csg/kang/MetaboChip/], or the ITMAT-Broad-CARe [IBC] for cardiovascular related traits, or the immunochip for immune related diseases) or sequencing. Furthermore, multiethnic genetic association studies have been recognized as potentially more powerful for both gene discovery and fine mapping [McCarthy et al., 2008; Pulit et al., 2010; Rosenberg et al., 2010; Teo et al., 2010] and some initial efforts have been carried out [He et al., 2011; Keebler et al., 2010; Lanktree et al., 2009; Lettre et al., 2011; Smith et al., 2011; Waters et al., 2009] . In addition, because GWAS-identified SNPs (mostly common) explain only a small proportion of overall heritability for most complex diseases and traits [Eichler et al., 2010; Maher, 2008; Manolio et al., 2009 ], whole-genome or whole-exome sequencing for rare SNPs and genetic variants other than SNPs (e.g., copy number variations, structural variants) are under way.
So far, there has been relatively little research on the performance of genotype imputation in this new context. Our study provides a typical scenario where we had genotyped 8,421 African Americans from the Women's Health Initiative (WHI) [Anderson et al., 1998 ] SNP Health Association Resource (SHARe) using the Affymetrix 6.0 genotyping platform. In an attempt to generalize genetic effects across racial groups, the Population Architecture using Genomics and Epidemiology (PAGE) consortium genotyped a subset of 1,962 African American WHI participants with data on multiple metabolic-related phenotypes using the Metabochip . To increase our power to detect moderate to small genetic effects, we sought to impute the Metabochip SNPs in the remaining 6,459 individuals in WHI SHARe with Affymetrix 6.0 data only. Imputing SNPs in the fine-mapping region tends to be more challenging because these SNPs tend to be rare and in low linkage disequilibrium (LD) with GWAS SNPs. Here, we describe a pipeline for constructing study-specific reference panels using individuals genotyped or sequenced at a larger set of genetic markers (in our case, individuals genotyped using both Affymetrix 6.0 and Metabochip) and for imputation into individuals with genotype data at a subset of markers (in our case, individuals genotyped using Affymetrix 6.0 only). We benchmark the quality of our imputation in an African American population, for SNPs on the Metabochip, a region-centric genotyping platform, with particular focus on low-frequency SNPs (MAF down to 0.001), using a large study-specific reference panel containing 3,924 haplotypes. An African American sample poses a greater challenge for genotype imputation due to more complex LD patterns in African Americans compared with individuals of European ancestry [Egyud et al., 2009; Shriner et al., 2009] , and in which comparatively less discovery work has been done.
We first describe how we constructed our study-specific reference panel using the 1,962 African American individuals with genotypes for both Affymetrix 6.0 and Metabochip SNPs and how we performed imputation of the Metabochip-only SNPs into the remaining 6,459 individuals. We then show several approaches through which we estimated imputation quality for SNPs in different MAF categories, with a special focus on less common (MAF: 0.01-0.05) and rare (MAF < 0.01) variants. We provide practical guidelines regarding post-imputation quality control for different MAF categories, as well as for the inclusion of rare variants during imputation.
MATERIALS AND METHODS

PRE-IMPUTATION QUALITY CONTROL
Prior to phasing and imputation, quality control was applied to both the Metabochip data and the GWAS data. Specifically, for the GWAS dataset (n = 6,459) we removed Affymetrix 6.0 SNPs with genotype call rates < 90% (m = 1,633), or Hardy-Weinberg exact test [Wigginton et al., 2005 ] P-value < 10 −6 (m = 16,327), or MAF < 0.01 (m = 14,014), resulting in a 829,370 GWAS SNPs passing quality control criteria . Separate quality control criteria were applied to the Metabochip SNPs, leading to 182,397 QC + SNPs with genotype call rates >95% and HardyWeinberg P-value > 10 −6 . Individuals were excluded if they had a call rate below 95%, showed excess heterozygosity, were part of an apparent first-degree relative pair, or were ancestry outliers as determined by Eigensoft [Price et al., 2006] . Details can be found in the PAGE Metabochip platform paper . Figure 1 shows schematically how imputation was performed. In the top left panel, we first merged genotypes from the Affymetrix GWAS panel (blue) and the Metabochip (yellow) SNPs genotyped as part of the PAGE study for the 1,962 reference individuals (i.e., individuals with genotype data from both platforms). We then reconstructed haplotypes encompassing both GWAS and Metabochip SNPs for the reference individuals, constituting the reference panel of 3,924 haplotypes. In the top right panel, haplotype reconstruction for target individuals (i.e., individuals with GWAS genotypes only) was carried out similarly, but at the GWAS markers only. Finally, a haplotype-to-haplotype (that is, data are in haplotype form for both the reference and target individuals) imputation was performed to generate estimated genotypes at the Metabochip SNPs for the 6,459 target individuals.
GENERAL PIPELINE FOR REFERENCE CONSTRUCTION AND SUBSEQUENT IMPUTATION
RESULTS
GENOMEWIDE IMPUTATION USING LARGE STUDY-SPECIFIC REFERENCE
After careful matching on strand (so that genotypes from both Affymetrix 6.0 and the Metabochip are on the same strand), SNP ID, genomic coordinates, and actual genotypes for SNPs in common, we had a merged set of 987,749 SNPs for the 1,962 reference individuals. The average concordance rate for the 23,703 SNPs in common was 99.7%. For discordant genotypes, we kept the GWAS genotypes to match those of the target individuals with GWAS data only. Haplotypes were reconstructed on the merged set using MaCH [Li et al., 2010b] . In parallel, we constructed haplotypes across the 829,370 QC + GWAS SNPs for all 8,421 individuals. Finally, we used the 3,924 haplotypes across the merged set of 987,749 SNPs as reference to impute into haplotypes across GWAS SNPs of the target individuals. The final haplotype-to-haplotype imputation was performed using the software package minimac, which generates the allele dosages (the fractional counts of an arbitrary allele at each SNP for each individual, ranging continuously from 0 to 2). Minimac also generates the SNPlevel quality metric Rsq, which is the SNP-specific estimated r 2 between allele dosages and the unknown true genotypes. Rsq has been recommended as an efficient postimputation quality control metric. Rsq, estimated r 2 , and estimated imputation r 2 are used interchangeably in the literature [Browning and Browning, 2009; Li et al., 2009] .
QUALITY ESTIMATE BY MASKING GENOTYPES AT 2% GWAS SNPs
Aside from production (actual imputation presented in the section above), we randomly masked 2% of the GWAS SNPs among the target individuals in the minimac imputation step to estimate the true imputation accuracy as well as to evaluate the utility of Rsq as a quality metric. By comparing imputed dosages with experimental genotypes, we and others have proposed several statistics to measure true imputation accuracy [Browning and Browning, 2009; Li et al., 2009; Lin et al., 2010; Marchini and Howie, 2010] , measuring either the concordance rate, correlation, or degree of agreement. Here, we choose to report the dosage r 2 , which is the squared Pearson correlation between the estimated allele dosages and the true experimental genotypes (recoded as 0, 1, and 2 corresponding to the number of minor alleles), because it is a more informative measure for low frequency variants by taking allele frequency into account and because it is directly related to the effective sample size for subsequent association analysis [Pritchard and Przeworski, 2001] . As dosage r 2 is calculated using the true genotypes (assuming the experimental genotypes are the true genotypes), people also call it true r 2 . Like Rsq, dosage r 2 is also specific to each SNP. Figure 2 shows the average dosage r 2 values for the 2% masked GWAS SNPs by chromosome. Genome-wide average is 93.68% (range 87.18 [chromosome 19] to 95.26% [chromosome 10]). As expected, larger chromosomes (in terms of physical length) tend to be slightly easier to impute due to slightly lower recombination rates and therefore higher level of LD [The International HapMap Consortium, 2005] . Chromosome 19, with the highest gene density, is most challenging for imputation. Table I shows the average dosage r 2 values by MAF. Not surprisingly, lower frequency variants are harder to impute due to poorer coverage by GWAS SNPs, lower degree of LD, and more challenging haplotype reconstruction. For example, the average dosage r 2 for SNPs with MAF > 0.05 is 95.08%; while the average for SNPs with MAF 0.005-0.01 is 70.84%.
While Figure 2 and Table I show the true imputation accuracy, in practice, we are more interested in how well imputation quality metrics can predict true imputation accuracy (measured by dosage r 2 ). Figure 3 assesses the quality metric Rsq by plotting it against dosage r 2 . We can see that Rsq can predict dosage r 2 quite well, particularly for common SNPs and those with reasonable Rsq values. For example, the Pearson correlation is 0.938 for all SNPs (regardless of MAF and Rsq), 0.952 for SNPs with MAF > 0.03 (regardless of Rsq), and 0.955 for SNPs with MAF > 0.03 and Rsq > 0.3.
Whereas masking GWAS SNPs is a simple approach to estimate imputation accuracy, the approach estimates imputation quality for the "wrong" set of SNPs in that we are imputing genotypes for Metabochip SNPs, not GWAS SNPs. The two set of SNPs differ in two major aspects: MAF and physical density distribution. First, in terms of allele frequency distribution, while Affymetrix 6.0 SNPs, like most commercially available genome-wide genotyping platforms, contain SNPs that are mostly common, the Metabochip platform contains a much larger proportion of lower frequency variants. For example, while only 4.3% and 9.9% of the Affymetrix SNPs have MAF < 0.03 and < 0.05, respectively, the proportions are 29.8% and 37.8% for Metabochip SNPs. Supplementary Figure 1 shows the MAF distributions of the Affymetrix 6.0 SNPs and the Metabochip SNPs. Second, the physical distribution of the SNPs is quite different. The Affymetrix 6.0 SNPs are rather evenly spread across the genome. SNPs on the Metabochip, chosen for fine mapping of regions identified through GWAS to be associated with metabolic-related traits, scatter unevenly across the genome and are concentrated around GWAS-identified signals. Supplementary Figure 2 shows two typical regions where the GWAS SNP density (green) is quite uniform across the region, while Metabochip SNP density (red) peaks in a subregion chosen for follow-up but drops sharply outside the subregion of interest.
QUALITY ESTIMATE BY MASKING GENOTYPES AT METABOCHIP SNPs FOR A SUBSET OF REFERENCE INDIVIDUALS
To estimate the imputation quality for the actually imputed Metabochip SNPs, we masked Metabochip genotypes for 100 reference individuals, imputed them, and compared the estimated dosages with the masked experimental genotypes. Note that we used haplotypes constructed from GWAS data only for the 100 individuals. Supplementary Figure 3 shows the average dosage r 2 by chromosome. Again imputation quality is slightly higher for larger chromosomes and lowest for chromosome 19. Table II presents imputation accuracy by MAF, with and without post-imputation filtering according to Rsq. First, it is clear that lower frequency variants are harder to impute. We and others have shown earlier that imputation accuracy increases with the reference panel size, especially for the imputation of lower frequency variants [Li et al., 2009; Marchini and Howie, 2010; The International HapMap Consortium, 2010] . However, even with a reference panel of 3,924 haplotypes, we are not able to obtain reasonable imputed data for SNPs with MAF under 0.001. Without post-imputation filtering, the average dosage r 2 is merely 0.39%. If we apply a post-imputation filter of Rsq > 0.3 (>0.5), only 0.4% (0.3%) of the SNPs with MAF < 0.001 pass the filter with an average dosage r 2 of 24.85% (30.45%). For this rarest category of SNPs (MAF < 0.001), even at an Rsq threshold of 0.95, which retains merely 23 of 18,959 SNPs, we can only achieve an average dosage r 2 of 47.82% (Fig. 4(a) 
OVERALL IMPUTATION PERFORMANCE AND PRACTICAL GUIDELINES
In practice, we recommend using Rsq as the postimputation quality control metric. Figure 5 attests to the high correlation between Rsq and dosage r 2 . We observe that the vast majority of SNPs are both imputed well and are predicted to be well imputed, corresponding to the biggest point masses (red to yellow range according to SNP frequency/count spectrum) with both high The sample size for SNPs with MAF < 0.001 is too small for conclusions, but the pattern suggests that the few SNPs passing the post imputation filter of Rsq > 0.5 are well imputed. In general, we recommend selecting an Rsq threshold such that the average Rsq is above the desired average dosage r 2 .
TO INCLUDE OR NOT TO INCLUDE: RARE SNPs DURING HAPLOTYPE RECONSTRUCTION
One open question concerns whether rare SNPs should be included for haplotype reconstruction, either for the reference individuals or for the target individuals. For the reference panel construction, on one hand, we would like to include as many variants as possible so that they can be subsequently imputed in the target individuals. On the other hand, inclusion of very rare SNPs may interfere with phasing (in the extreme case, for example, singletons cannot be phased), resulting in less accurately constructed haplotypes, and ultimately leading to inferior imputation quality, with little or no benefit in return because these very rare SNPs are unlikely to be accurately imputed into the target individuals. Similarly, for the target individuals, inclusion of rare SNPs may harm phasing quality, leading to less accurate imputation. On the other hand, as rare to-be-imputed SNPs are more likely to be tagged by rare GWAS SNPs than by common GWAS SNPs, inclusion of rare GWAS variants is expected to increase imputation quality for rarer SNPs. To evaluate this, we assessed the following 20 combinations by varying two parameters: MAF threshold used for the reference panel construction and MAF threshold used for phasing target individuals. For the reference panel construction, we evaluated the following four settings: (A) all MAF (i.e., no filtering by MAF); (B) no singletons (i.e., removing SNPs with only one copy of the minor allele among the 8,421 individuals with GWAS data); (C) MAF > 0.001; and (D) MAF > 0.005. For phasing target individuals, we evaluated the following five settings: (i) all MAF; (ii) no singletons (i.e., removing SNPs with only one copy of the minor allele among reference); (iii) MAF > 0.001; (iv) MAF > 0.005; and (v) MAF > 0.01. Note that for our production imputation, we used (v) MAF > 0.01. We picked a medium size chromosome, chromosome 12, for evaluation.
As the comparisons among the four settings for building the reference panel show similar patterns across the five settings for target haplotype reconstruction and vice versa, we present the average of all settings defined by the other parameter. For example, Table III (Table IV) . Removing SNPs with MAF < 0.001 or 0.005 (settings iii and iv) is slightly advantageous for imputing SNPs with MAF 0.001-0.01. For example, with an Rsq threshold of 0.3, average dosage r 2 for SNPs with MAF 0.001-0.005 is 85.6% and 84.0%, respectively, for settings iii and iv; while dosage r 2 for the other three settings is ≤ 83.0%. However, these settings result in slightly lower imputation quality for SNPs with MAF 0.01-0.05. For example, with an Rsq threshold of 0.3, average dosage r 2 for SNPs with MAF 0.01-0.03 is 90.4% (for 1,255 SNPs) and 90.6% (for 1,269 SNPs), respectively, for settings iii and iv; while dosage r 2 for the other three settings is ≥ 91.0% for a larger number of SNPs (number of SNPs ≥ 1,289).
DISCUSSION
As we are moving into the sequencing era, existing GWAS data provide an inexpensive opportunity to leverage expensive sequencing data. Researchers across the world are becoming increasingly keen on imputation as a tool to infer genotypes at less common (MAF 0.01-0.05) and rare (MAF < 0.01) variants. We have previously shown that larger reference panels improve imputation accuracy for less common variants. In particular, enlarging a reference panel of 60 haplotypes to 1,000 haplotypes increases dosage r 2 for SNPs with MAF < 0.05 from 74% to 93% [Li et al., 2010a] . However, there has been little, if any, research on truly rare variants: it is not until recently that we have data available to assess imputation accuracy for these truly rare variants. Here, we used a reference panel of 3,924 reference haplotypes to demonstrate that it is indeed possible to impute a considerable proportion of rare variants reasonably well, even in a challenging admixed sample of African Americans. Specifically (as indicated in bold in Table II) , we were able to impute 99.9% (97.5%, 83.6%, 52.0%, 20.5%) of SNPs with MAF > 0. 05 (0.03-0.05, 0.01-0.03, 0.005-0.01, and 0.001-0.005 ) with average dosage r 2 94. 7% (92.1%, 89.0%, 83.1%, and 79.7%) .
In the previous section, we presented results from masking Metabochip genotypes for 100 reference individuals during minimac imputation, whom we also included along with the other 1,862 individuals during reference panel construction. One may reasonably argue that the inclusion of the 100 individuals during phasing results in local haplotype mosaics of other individuals better matching haplotypes of these 100 individuals (because constructed haplotypes of the 100 individuals are likely to serve as template to construct haplotypes of other individuals), and therefore over-estimated imputation accuracy. We evaluated this potential over-estimation of imputation accuracy by re-constructing the reference panel only on the other 1,862 individuals. Table V compares We observed no obvious over-estimation: the quality is either very close; or one has slightly smaller number of well-imputed SNPs with slightly higher dosage r 2 than the other. For example, for SNPs with MAF 0.001-0.005, when using Rsq > 0.3 as the post-imputation filter, the reference constructed using 1,862 individuals resulted in slightly fewer (117) SNPs passing the filter with a slightly better average dosage r 2 (84.1%), than the reference constructed using 1,962 individuals which had 123 SNPs passing the filter with an average dosage r 2 of 82.3%. The over-estimation may manifest itself if the reference panel were smaller because the 100 masked individuals would contribute more to the haplotype reconstruction of other reference individuals.
We would also like to note that masking 100 reference individuals, although allowing us to directly evaluate imputation quality at actually imputed Metabochip SNPs, still has limitations. For example, sample MAF cannot go below 0.005 and SNPs with "population" MAF (calculated based on n = 1,962 individuals) < 0.005 are either non-varying or have the minor allele over-represented among the 100 individuals (i.e., sample MAF > "population" MAF). Therefore, such SNPs are either not imputable (dosage r 2 un-defined and set to zero in our calculations) or tend to be easier to impute than a typical SNP in the population MAF category. The latter case leads to a winner's curse phenomenon such that the actual imputation quality tends to be overestimated. In order to obtain more reliable estimates for the rarest MAF categories, we attempted a slightly more complicated experiment on chromosome 12 where we masked one reference individual at a time and imputed her genotypes at Metabochip SNPs using other reference individuals' haplotypes. This experiment allows us to examine a sample size of 1,962 instead of 100.
The overall recommendation of picking an Rsq threshold such that the average Rsq is at least 80% to achieve an average dosage r 2 of 80% or above still applies. However, compared with results based on 100 individuals, the actual Rsq thresholds selected for the rare MAF categories are considerably larger, but result in the passing of a larger proportion of SNPs. For example, an Rsq threshold of 0.75 (instead of 0.5 based on the 100 individuals) needs to be applied for SNPs with MAF 0.001-0.005 for the average Rsq to be above 80%, passing 38.8% (instead of 20.5% SNPs). The larger Rsq threshold and larger passing proportion are consistent with the winner's curse phenomenon we discuss above. For example, for SNPs with population MAF 0.001-0.005, the vast majority of SNPs are monomorphic among the 100 individuals and thus have Rsq close to zero, reflected by the fact that 68.7% of SNPs have Rsq < 0.1 (Fig. 4(b) ). For the small proportion of SNPs that have reasonable Rsq (Rsq > 0.3), which is the proportion of SNPs with minor allele either over-represented or in more extensive LD with neighboring SNPs among the sample of 100 masked individuals, the distribution is highly skewed toward high values. For example, among the 20.5% SNPs with Rsq > 0.5, 16.9% (or 82.0% of the 20.5%) have Rsq > 0.75 such that the average Rsq is 89.24%. In contrast, a much larger proportion of SNPs are no longer monomorphic among the 1,962 individuals and better represent the full range of SNPs in these rare MAF categories, specifically by adding the more challenging SNPs (SNPs with less or no over-representation of the minor allele, and SNPs with less extensive LD with neighboring SNPs Although this study examines an African American population genotyped using Affymetrix 6.0 platform, the recommendation to use Rsq threshold such that average Rsq is around but over the desired dosage r 2 value is generalizable to other populations and other GWAS genotyping platforms, based on similar experiments conducted in several European and Asian populations using different choices of genotyping platforms. For example, in a sample of Filipinos [Wu et al., 2010] genotyped using the Affymetrix 5.0 platform, we found applying a filter of Rsq > 0.6 for SNPs with MAF 0.01-0.02, the average dosage r 2 across the SNPs passing the filter was 0.8085 with an average Rsq of 0.8417. Additional assessment in other populations or using other GWAS platforms can be found in our earlier work [Li et al., , 2010b . Before more data become available, however, caution needs to be taken when applying the recommendation to rare variants. For example, although imputation in general is more difficult in African populations because of more combinations of the common alleles, recent work [Fumagalli et al., 2010; Gravel et al., 2011] argue that the more distinctive background of common alleles may benefit imputation of rare variants. In addition, tagSNPs on the Affymetrix 6.0 platform were selected largely based on physical positions, in contrast to those on the Illumina platforms that were selected largely to provide good coverage of the common SNPs according to HapMap-based LD. Therefore, the Affymetrix 6.0 platform may perform better for rare SNP imputation, particularly in samples of nonEuropean ancestry.
Our sample consist of females only, therefore, it is straightforward to perform imputation on chromosome X. Even for samples including males, widely used imputation methods can now perform X chromosome imputation (see http://genome.sph.umich.edu/wiki/MaCH: machX and [Marchini and Howie, 2010] ). We did not attempt chromosome X in our dataset because there are only 93 QC+ Metabochip SNPs on chromosome X. In summary, by constructing a study-specific reference panel of 3,924 haplotypes, we found it feasible to impute SNPs on the Metabochip, a region-centric dense genotyping platform, in a sample of African Americans, including less common SNPs with MAF 0.005-0.05. In addition, we confirmed Rsq as an effective imputation quality metric for these less common variants. In particular, we recommend different Rsq thresholds for different MAF categories such that the average Rsq is above 80%. Furthermore, we found it helpful to remove singleton SNPs when constructing reference haplotypes.
We view this work useful for investigators conducting fine-mapping studies using either dense genotyping or next generation sequencing, particularly for studies in nonEuropean populations. Many efforts to fine map, especially in non-European ancestry participants, are limited by small sample sizes. Now that there are increasing numbers of GWAS studies conducted in non-European populations, imputation can provide a good solution to this sample size problem. For admixed samples like those in our study, new methods are being developed that both leverage the admixture for phenotype-genotype association mapping and take imputation uncertainty into account [Mao et al., 2011; Pasaniuc et al., 2011] .
